NCT03071874View on ClinicalTrials.gov

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

PHASE2UnknownINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 17, 2017

Primary Completion Date

June 30, 2022

Study Completion Date

July 25, 2024

Conditions
Meningioma
Interventions
DRUG

AZD2014

AZD2014 is a dual mTORC1/mTORC2 inhibitor

Trial Locations (3)

60611

Northwestern University, Chicago

02114

Massachusetts general Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

AstraZeneca

INDUSTRY

lead

Massachusetts General Hospital

OTHER